According to incomplete statistics, the commonly used anti-tumor drugs in the clinical treatment of carcinoma, such as 5-fluorouracil, cisplatin, gemcitabine, paclitaxel, crizotinib, oxaliplatin, niraparib, and tamoxifen, had higher IC50 values (worse efficacy) in patients with high TAGLN2 expression (Figure S7). This evidence concerns the gene TAGLN2 and carcinoma.